Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer
There was no difference in the median progression‐free survival for combination tremelimumab plus durvalumab compared to tremelimumab alone (administered as part of a sequential treatment strategy) in a heavily pretreated population of patients with platinum‐resistant high‐grade serous ovarian cance...
Saved in:
| Published in | Cancer Vol. 130; no. 7; pp. 1061 - 1071 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley Subscription Services, Inc
01.04.2024
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | There was no difference in the median progression‐free survival for combination tremelimumab plus durvalumab compared to tremelimumab alone (administered as part of a sequential treatment strategy) in a heavily pretreated population of patients with platinum‐resistant high‐grade serous ovarian cancer. The adverse event profile was consistent with that previously reported for immune checkpoint blockade, and patient‐reported outcomes were similar in both arms. |
|---|---|
| AbstractList | Single-agent immune checkpoint inhibitors (ICIs) have demonstrated limited responses in recurrent ovarian cancer; however, 30%-40% of patients achieve stable disease. The primary objective was to estimate progression-free survival (PFS) after sequential versus combination cytotoxic T-lymphocyte antigen 4 and programmed death ligand 1 ICIs in patients with platinum-resistant high-grade serous ovarian cancer (HGSOC).
Patients were randomized to a sequential arm (tremelimumab followed by durvalumab on progression) or a combination arm (tremelimumab plus durvalumab, followed by durvalumab) via a Bayesian adaptive design that made it more likely for patients to be randomized to the more effective arm. The primary end point was immune-related PFS (irPFS).
Sixty-one subjects were randomized to sequential (n = 38) or combination therapy (n = 23). Thirteen patients (34.2%) in the sequential arm received durvalumab. There was no difference in PFS in the sequential arm (1.84 months; 95% CI, 1.77-2.17 months) compared with the combination arm (1.87 months; 95% CI, 1.77-2.43 months) (p = .402). In the sequential arm, no responses were observed, although 12 patients (31.6%) demonstrated stable disease. In the combination arm, two patients (8.7%) had partial response, whereas one patient (4.4%) had stable disease. Adverse events were consistent with those previously reported for ICIs. Patient-reported outcomes were similar in both arms.
There was no difference in irPFS for combination tremelimumab plus durvalumab compared to tremelimumab alone (administered as part of a sequential treatment strategy) in a heavily pretreated population of patients with platinum-resistant HGSOC. Response rates were comparable to prior reports, although the combination regimen did not add significant benefit, as has been previously described. There was no difference in the median progression‐free survival for combination tremelimumab plus durvalumab compared to tremelimumab alone (administered as part of a sequential treatment strategy) in a heavily pretreated population of patients with platinum‐resistant high‐grade serous ovarian cancer. The adverse event profile was consistent with that previously reported for immune checkpoint blockade, and patient‐reported outcomes were similar in both arms. Single-agent immune checkpoint inhibitors (ICIs) have demonstrated limited responses in recurrent ovarian cancer; however, 30%-40% of patients achieve stable disease. The primary objective was to estimate progression-free survival (PFS) after sequential versus combination cytotoxic T-lymphocyte antigen 4 and programmed death ligand 1 ICIs in patients with platinum-resistant high-grade serous ovarian cancer (HGSOC).BACKGROUNDSingle-agent immune checkpoint inhibitors (ICIs) have demonstrated limited responses in recurrent ovarian cancer; however, 30%-40% of patients achieve stable disease. The primary objective was to estimate progression-free survival (PFS) after sequential versus combination cytotoxic T-lymphocyte antigen 4 and programmed death ligand 1 ICIs in patients with platinum-resistant high-grade serous ovarian cancer (HGSOC).Patients were randomized to a sequential arm (tremelimumab followed by durvalumab on progression) or a combination arm (tremelimumab plus durvalumab, followed by durvalumab) via a Bayesian adaptive design that made it more likely for patients to be randomized to the more effective arm. The primary end point was immune-related PFS (irPFS).METHODSPatients were randomized to a sequential arm (tremelimumab followed by durvalumab on progression) or a combination arm (tremelimumab plus durvalumab, followed by durvalumab) via a Bayesian adaptive design that made it more likely for patients to be randomized to the more effective arm. The primary end point was immune-related PFS (irPFS).Sixty-one subjects were randomized to sequential (n = 38) or combination therapy (n = 23). Thirteen patients (34.2%) in the sequential arm received durvalumab. There was no difference in PFS in the sequential arm (1.84 months; 95% CI, 1.77-2.17 months) compared with the combination arm (1.87 months; 95% CI, 1.77-2.43 months) (p = .402). In the sequential arm, no responses were observed, although 12 patients (31.6%) demonstrated stable disease. In the combination arm, two patients (8.7%) had partial response, whereas one patient (4.4%) had stable disease. Adverse events were consistent with those previously reported for ICIs. Patient-reported outcomes were similar in both arms.RESULTSSixty-one subjects were randomized to sequential (n = 38) or combination therapy (n = 23). Thirteen patients (34.2%) in the sequential arm received durvalumab. There was no difference in PFS in the sequential arm (1.84 months; 95% CI, 1.77-2.17 months) compared with the combination arm (1.87 months; 95% CI, 1.77-2.43 months) (p = .402). In the sequential arm, no responses were observed, although 12 patients (31.6%) demonstrated stable disease. In the combination arm, two patients (8.7%) had partial response, whereas one patient (4.4%) had stable disease. Adverse events were consistent with those previously reported for ICIs. Patient-reported outcomes were similar in both arms.There was no difference in irPFS for combination tremelimumab plus durvalumab compared to tremelimumab alone (administered as part of a sequential treatment strategy) in a heavily pretreated population of patients with platinum-resistant HGSOC. Response rates were comparable to prior reports, although the combination regimen did not add significant benefit, as has been previously described.CONCLUSIONSThere was no difference in irPFS for combination tremelimumab plus durvalumab compared to tremelimumab alone (administered as part of a sequential treatment strategy) in a heavily pretreated population of patients with platinum-resistant HGSOC. Response rates were comparable to prior reports, although the combination regimen did not add significant benefit, as has been previously described. BackgroundSingle‐agent immune checkpoint inhibitors (ICIs) have demonstrated limited responses in recurrent ovarian cancer; however, 30%–40% of patients achieve stable disease. The primary objective was to estimate progression‐free survival (PFS) after sequential versus combination cytotoxic T‐lymphocyte antigen 4 and programmed death ligand 1 ICIs in patients with platinum‐resistant high‐grade serous ovarian cancer (HGSOC).MethodsPatients were randomized to a sequential arm (tremelimumab followed by durvalumab on progression) or a combination arm (tremelimumab plus durvalumab, followed by durvalumab) via a Bayesian adaptive design that made it more likely for patients to be randomized to the more effective arm. The primary end point was immune‐related PFS (irPFS).ResultsSixty‐one subjects were randomized to sequential (n = 38) or combination therapy (n = 23). Thirteen patients (34.2%) in the sequential arm received durvalumab. There was no difference in PFS in the sequential arm (1.84 months; 95% CI, 1.77–2.17 months) compared with the combination arm (1.87 months; 95% CI, 1.77–2.43 months) (p = .402). In the sequential arm, no responses were observed, although 12 patients (31.6%) demonstrated stable disease. In the combination arm, two patients (8.7%) had partial response, whereas one patient (4.4%) had stable disease. Adverse events were consistent with those previously reported for ICIs. Patient‐reported outcomes were similar in both arms.ConclusionsThere was no difference in irPFS for combination tremelimumab plus durvalumab compared to tremelimumab alone (administered as part of a sequential treatment strategy) in a heavily pretreated population of patients with platinum‐resistant HGSOC. Response rates were comparable to prior reports, although the combination regimen did not add significant benefit, as has been previously described. |
| Author | Hinchcliff, Emily M. Adjei, Naomi Vikram, Raghunandan Vining, David Sood, Anil K. Jazaeri, Amir A. Fleming, Nicole D. Ganeshan, Dhakshina M. Lu, Karen H. Sun, Charlotte C. Soliman, Pamela T. Westin, Shannon N. Shafer, Aaron Gershenson, David M. Knisely, Anne Yuan, Ying Bathala, Tharakeswara Patel, Ami Fellman, Bryan Meyer, Larissa A. Xu, Cai |
| Author_xml | – sequence: 1 givenname: Emily M. surname: Hinchcliff fullname: Hinchcliff, Emily M. organization: Department of Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 2 givenname: Anne orcidid: 0000-0003-4200-2293 surname: Knisely fullname: Knisely, Anne organization: Department of Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 3 givenname: Naomi surname: Adjei fullname: Adjei, Naomi organization: Department of Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 4 givenname: Bryan surname: Fellman fullname: Fellman, Bryan organization: Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 5 givenname: Ying surname: Yuan fullname: Yuan, Ying organization: Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 6 givenname: Ami surname: Patel fullname: Patel, Ami organization: Department of Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 7 givenname: Cai surname: Xu fullname: Xu, Cai organization: Department of Symptom Research The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 8 givenname: Shannon N. surname: Westin fullname: Westin, Shannon N. organization: Department of Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 9 givenname: Anil K. orcidid: 0000-0003-4242-1762 surname: Sood fullname: Sood, Anil K. organization: Department of Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 10 givenname: Pamela T. orcidid: 0000-0002-8784-9212 surname: Soliman fullname: Soliman, Pamela T. organization: Department of Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 11 givenname: Aaron surname: Shafer fullname: Shafer, Aaron organization: Department of Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 12 givenname: Nicole D. orcidid: 0000-0003-1785-4072 surname: Fleming fullname: Fleming, Nicole D. organization: Department of Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 13 givenname: David M. surname: Gershenson fullname: Gershenson, David M. organization: Department of Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 14 givenname: Raghunandan surname: Vikram fullname: Vikram, Raghunandan organization: Department of Radiology The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 15 givenname: Tharakeswara surname: Bathala fullname: Bathala, Tharakeswara organization: Department of Radiology The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 16 givenname: David surname: Vining fullname: Vining, David organization: Department of Radiology The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 17 givenname: Dhakshina M. surname: Ganeshan fullname: Ganeshan, Dhakshina M. organization: Department of Radiology The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 18 givenname: Karen H. surname: Lu fullname: Lu, Karen H. organization: Department of Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 19 givenname: Charlotte C. surname: Sun fullname: Sun, Charlotte C. organization: Department of Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 20 givenname: Larissa A. orcidid: 0000-0002-2687-7463 surname: Meyer fullname: Meyer, Larissa A. organization: Department of Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA – sequence: 21 givenname: Amir A. surname: Jazaeri fullname: Jazaeri, Amir A. organization: Department of Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38009662$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkctqVTEUhoNU7Gl14gNIwEkRdk2ysy8ZSvEGBUEUnIXsZAVTcjkmOwfakfNOfEafxJzTdlIcJevn-1dW1n-CjmKKgNBLSs4pIeytjjqf9wNl4xO0oURMHaGcHaENIWTuBt7_OEYnpVy1cmJD_wwd9zMhYhzZBt1-VdGk4G7A4O1PVQAzvGanPE62XSCAd6EGteDGYVPzTvlD6SLWKSwuqtWliHeQSy24wK8KcW1-f71HMuiac1Pw1jcw1vD3958MxZVVNTHtVHurdVJRQ36OnlrlC7y4P0_R9w_vv1186i6_fPx88e6y0-2TaycmDkZrvgxWKWuUFpwK4JPurZq0YMYOdDRmmK1YiLHQdEZ7DmTUMx_t1J-is7u-25zauGWVwRUN3qsIqRbJZsEn1jNBGvr6EXqVao5tOslEPzM282Fo1Kt7qi4BjNxmF1S-lg9rbgC5A3ROpWSwUrv1sLg1K-clJXKfpNwnKQ9JNsubR5aHrv-B_wGOGaQP |
| CitedBy_id | crossref_primary_10_3389_fphar_2024_1490896 crossref_primary_10_1007_s40271_024_00689_4 crossref_primary_10_1136_jitc_2024_010959 crossref_primary_10_2478_ahem_2025_0004 crossref_primary_10_3390_biomedicines13010168 |
| Cites_doi | 10.1093/oncolo/oyac099 10.1001/jamanetworkopen.2022.26252 10.1186/s41687‐020‐00210‐z 10.1056/NEJMoa020177 10.1158/1078‐0432.CCR‐09‐1624 10.1200/JCO.2001.19.6.1809 10.1001/jamaoncol.2020.5945 10.1056/NEJMoa1712126 10.1056/NEJMoa1504030 10.2165/00019053‐200725050‐00002 10.1002/onco.13798 10.1001/jamaoncol.2018.6258 10.1016/j.ygyno.2013.05.009 10.1016/S1470‐2045(16)30126‐7 10.2165/11591720‐000000000‐00000 10.1200/JCO.19.02059 10.1002/cam4.4593 10.1002/cam4.4086 10.1007/s00520‐012‐1623‐4 10.1200/JCO.21.00334 10.1016/S1470‐2045(15)00544‐6 10.2307/2533377 10.1016/j.jbi.2008.08.010 10.1016/j.ejca.2007.01.006 10.1016/j.ejca.2008.10.026 10.3322/caac.21654 10.1056/NEJMoa1801946 10.1007/978‐3‐030‐41008‐7_7 10.1093/annonc/mdz135 10.1037/t29280‐000 |
| ContentType | Journal Article |
| Copyright | 2023 American Cancer Society. 2024 American Cancer Society. |
| Copyright_xml | – notice: 2023 American Cancer Society. – notice: 2024 American Cancer Society. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 |
| DOI | 10.1002/cncr.35126 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1097-0142 |
| EndPage | 1071 |
| ExternalDocumentID | 38009662 10_1002_cncr_35126 |
| Genre | Clinical Trial, Phase II Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: T32 CA101642 – fundername: NCI NIH HHS grantid: P50 CA217685 – fundername: NCI NIH HHS grantid: P30 CA016672 – fundername: NCI NIH HHS grantid: K07 CA201013 – fundername: NCI NIH HHS grantid: P50 CA281701 – fundername: NIH HHS grantid: CA217685 – fundername: NIH HHS grantid: CA016672 – fundername: NCRR NIH HHS grantid: M01 RR000847 – fundername: NCI NIH HHS grantid: R01 CA306089 – fundername: NIH HHS grantid: K07CA201013 |
| GroupedDBID | --- -~X .3N .GA .GJ .Y3 05W 0R~ 10A 1CY 1L6 1OC 29B 31~ 33P 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AAQOH AARRQ AAWTL AAXRX AAYCA AAYXX AAZKR ABCQN ABCUV ABEML ABHFT ABIJN ABIVO ABJNI ABLJU ABOCM ABPPZ ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUYR AEYWJ AFBPY AFFNX AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGNAY AGYGG AHBTC AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C1A C45 CITATION CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EJD EMOBN EX3 F00 F01 F04 F5P FD6 FUBAC G-S G.N GNP GODZA GX1 H.X HBH HF~ HGLYW HHY HHZ HZ~ H~9 IH2 IX1 J0M J5H JPC KBYEO KQQ KZ1 L7B LATKE LAW LC2 LC3 LH4 LITHE LMP LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NEJ NF~ NNB O66 O9- OHT OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 QRW R.K ROL RSU RX1 RYL SJN SUPJJ TEORI UDS UHB V2E V8K V9Y VH1 W8V W99 WBKPD WH7 WHG WHWMO WIH WIJ WIK WIN WJL WOHZO WQJ WVDHM WXI WXSBR XG1 XPP XV2 Y6R YQJ Z0Y ZGI ZXP ZZTAW ~IA ~WT AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c351t-974edcc4b5faafdac9419e47c3fa7c92df516dd58f9b0dfec3f2134e06c846f73 |
| ISSN | 0008-543X 1097-0142 |
| IngestDate | Fri Jul 11 10:03:41 EDT 2025 Sun Jul 13 04:45:45 EDT 2025 Sun Aug 31 01:36:49 EDT 2025 Thu Apr 24 23:11:03 EDT 2025 Tue Jul 01 04:09:45 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | ovarian neoplasms immune checkpoint inhibitors patient-reported outcome measures immunotherapy randomized controlled trial |
| Language | English |
| License | 2023 American Cancer Society. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c351t-974edcc4b5faafdac9419e47c3fa7c92df516dd58f9b0dfec3f2134e06c846f73 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Feature-2 ObjectType-Undefined-1 content type line 23 ObjectType-Article-3 |
| ORCID | 0000-0003-4200-2293 0000-0003-4242-1762 0000-0002-2687-7463 0000-0002-8784-9212 0000-0003-1785-4072 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/11267492 |
| PMID | 38009662 |
| PQID | 2938228455 |
| PQPubID | 2045183 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_2894723290 proquest_journals_2938228455 pubmed_primary_38009662 crossref_citationtrail_10_1002_cncr_35126 crossref_primary_10_1002_cncr_35126 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-04-00 2024-04-01 20240401 |
| PublicationDateYYYYMMDD | 2024-04-01 |
| PublicationDate_xml | – month: 04 year: 2024 text: 2024-04-00 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Atlanta |
| PublicationTitle | Cancer |
| PublicationTitleAlternate | Cancer |
| PublicationYear | 2024 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | e_1_2_9_30_1 e_1_2_9_31_1 e_1_2_9_11_1 e_1_2_9_10_1 e_1_2_9_13_1 e_1_2_9_12_1 e_1_2_9_15_1 e_1_2_9_14_1 e_1_2_9_17_1 e_1_2_9_16_1 e_1_2_9_19_1 e_1_2_9_18_1 e_1_2_9_20_1 e_1_2_9_22_1 e_1_2_9_21_1 e_1_2_9_24_1 e_1_2_9_23_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_9_1 e_1_2_9_26_1 e_1_2_9_25_1 e_1_2_9_28_1 e_1_2_9_27_1 e_1_2_9_29_1 |
| References_xml | – ident: e_1_2_9_18_1 doi: 10.1093/oncolo/oyac099 – ident: e_1_2_9_11_1 doi: 10.1001/jamanetworkopen.2022.26252 – ident: e_1_2_9_13_1 doi: 10.1186/s41687‐020‐00210‐z – ident: e_1_2_9_3_1 doi: 10.1056/NEJMoa020177 – ident: e_1_2_9_22_1 doi: 10.1158/1078‐0432.CCR‐09‐1624 – ident: e_1_2_9_26_1 doi: 10.1200/JCO.2001.19.6.1809 – ident: e_1_2_9_8_1 doi: 10.1001/jamaoncol.2020.5945 – ident: e_1_2_9_30_1 doi: 10.1056/NEJMoa1712126 – ident: e_1_2_9_31_1 doi: 10.1056/NEJMoa1504030 – ident: e_1_2_9_27_1 doi: 10.2165/00019053‐200725050‐00002 – ident: e_1_2_9_17_1 doi: 10.1002/onco.13798 – ident: e_1_2_9_7_1 doi: 10.1001/jamaoncol.2018.6258 – ident: e_1_2_9_24_1 doi: 10.1016/j.ygyno.2013.05.009 – ident: e_1_2_9_9_1 doi: 10.1016/S1470‐2045(16)30126‐7 – ident: e_1_2_9_20_1 doi: 10.2165/11591720‐000000000‐00000 – ident: e_1_2_9_10_1 doi: 10.1200/JCO.19.02059 – ident: e_1_2_9_15_1 doi: 10.1002/cam4.4593 – ident: e_1_2_9_12_1 doi: 10.1002/cam4.4086 – ident: e_1_2_9_25_1 doi: 10.1007/s00520‐012‐1623‐4 – ident: e_1_2_9_6_1 doi: 10.1200/JCO.21.00334 – ident: e_1_2_9_16_1 doi: 10.1016/S1470‐2045(15)00544‐6 – ident: e_1_2_9_21_1 doi: 10.2307/2533377 – ident: e_1_2_9_23_1 doi: 10.1016/j.jbi.2008.08.010 – ident: e_1_2_9_19_1 doi: 10.1016/j.ejca.2007.01.006 – ident: e_1_2_9_14_1 doi: 10.1016/j.ejca.2008.10.026 – ident: e_1_2_9_2_1 doi: 10.3322/caac.21654 – ident: e_1_2_9_29_1 doi: 10.1056/NEJMoa1801946 – ident: e_1_2_9_4_1 doi: 10.1007/978‐3‐030‐41008‐7_7 – ident: e_1_2_9_5_1 doi: 10.1093/annonc/mdz135 – ident: e_1_2_9_28_1 doi: 10.1037/t29280‐000 |
| SSID | ssj0007253 |
| Score | 2.4915643 |
| Snippet | There was no difference in the median progression‐free survival for combination tremelimumab plus durvalumab compared to tremelimumab alone (administered as... Single-agent immune checkpoint inhibitors (ICIs) have demonstrated limited responses in recurrent ovarian cancer; however, 30%-40% of patients achieve stable... BackgroundSingle‐agent immune checkpoint inhibitors (ICIs) have demonstrated limited responses in recurrent ovarian cancer; however, 30%–40% of patients... |
| SourceID | proquest pubmed crossref |
| SourceType | Aggregation Database Index Database Enrichment Source |
| StartPage | 1061 |
| SubjectTerms | Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - adverse effects Bayes Theorem Bayesian analysis Cancer Cytotoxicity Female Humans Immune Checkpoint Inhibitors Immunotherapy Lymphocytes Monoclonal antibodies Ovarian cancer Ovarian Neoplasms - drug therapy Patients Platinum Targeted cancer therapy |
| Title | Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38009662 https://www.proquest.com/docview/2938228455 https://www.proquest.com/docview/2894723290 |
| Volume | 130 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkKa9IO4UBjKCF1Rl5OYkfhxjaAKNh2mT9hY5vmid0rTqGqRO_AH-NefEzqWik4CXqLXdRun3-fQ7x8fHhLyPmIlkJpQH6iH1Yh4LjwvFPSYKZmRRCGZwo_Dp9-TkIv56yS5Ho5_D3SWr4kDebt1X8j-oQhvgirtk_wHZ7kuhAV4DvnAFhOH6VxifiUrNZ9NbEI2LK_g7moQTewoHLvxj4K-czuqZKJoVAlUvsbI3vrW55-ATW_QxM6O-mdisapjxZbm221ykK960wIS5qp554Juj3sT0gR_gZINtkMia5VDiHvUtTUi7kleydMUfj5toShfs-VbhYU9rm1jZr-8fqms9taYfnq4Xq2XpwrWflmtHahevCIdpLtraWB8LwAbxphF2qzOWbenApKLPutXW29qxspLLgwhkSzIcBDgtZg3qUYZemrP4m5W126575H4ITgaef_H5rC8-loYs6grahh_7G-2R3fajm2rmDhelkSrnD8kD52PQQ0uYR2Skq8dk99RlUTwhv3re0IY3NKQNb-jc0CFvKIyjPW_otKID3lDLGzrkDQ7peEP_5A11vKGWN0_JxZfj86MTzx3J4Ul49JUH3qdWUsYwkYUwSkgeB1zHqYyMSCUPlWFBohTLDC98ZTS0Y8lA7ScShK5Jo2dkp5pX-gWhgVYJzwJcl9AoEzPpGyNCn6s0KSRTY_Kh_Wlz6erV47EpZW4rbYc5IpI3iIzJu27swlZp2Tpqv0Uod7P4Jge5Cxo5ixkbk7ddN9hYXDgTlZ7XMCbjcQquB_fH5LlFtrtNy4SXd_a8Inv9PNgnO6tlrV-Dkl0VbxrC_Qa5-6f4 |
| linkProvider | Wiley-Blackwell |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Randomized+phase+2+trial+of+tremelimumab+and+durvalumab+in+combination+versus+sequentially+in+recurrent+platinum-resistant+ovarian+cancer&rft.jtitle=Cancer&rft.au=Hinchcliff%2C+Emily+M&rft.au=Knisely%2C+Anne&rft.au=Adjei%2C+Naomi&rft.au=Fellman%2C+Bryan&rft.date=2024-04-01&rft.eissn=1097-0142&rft.volume=130&rft.issue=7&rft.spage=1061&rft_id=info:doi/10.1002%2Fcncr.35126&rft_id=info%3Apmid%2F38009662&rft.externalDocID=38009662 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |